Hepatotoxicity induced by new immunosuppressants;Toxicidad hepática inducida por los nuevos fármacos inmunosupresores

Gastroenterologia y Hepatologia

Volumn 33, Issue 1, 2010, Pages 54-65

  Toscano, Elena ^a   Cotta, Judit ^a   Robles, Mercedes ^a,b   Lucena, Ma Isabel ^a,b   Andrade, Raúl J ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Anti TNF ; Hepatotoxicity; Immunosuppressants; Infliximab.; Liver damage

Indexed keywords

ADALIMUMAB; ALEFACEPT; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; RAPAMYCIN; TACROLIMUS; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACNE; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CATARACT; CHOLELITHIASIS; CHOLESTASIS; CHRONIC HEPATITIS; CROHN DISEASE; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; ENTERITIS; FATTY LIVER; GLUCOSE INTOLERANCE; GRAFT REJECTION; HEPATITIS; HEPATITIS B; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IDIOPATHIC DISEASE; INSOMNIA; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY GRAFT REJECTION; LIVER CANCER; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER FOCAL NODULAR HYPERPLASIA; LIVER GRANULOMA; LIVER INJURY; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LYMPHOMA; MENTAL INSTABILITY; NEPHROTOXICITY; NEUROTOXICITY; OSTEOPENIA; PELIOSIS HEPATIS; PORTAL HYPERTENSION; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPLEEN CANCER; ULCERATIVE COLITIS; VASCULITIS;

AZATHIOPRINE; CYCLOSPORINE; DRUG-INDUCED LIVER INJURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; METHOTREXATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73549091449     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2009.07.003     Document Type: Article

References (109)

1. García-Cortés M., Andrade R.J., Lucena M.I., González-Grande R., Camargo R., Fernández-Bonilla E., et al. Hepatotoxicity due to commonly-used drugs. Gastroenterol Hepatol 28 (2005) 461-472
2. Andrade R.J., Lucena M.I., Fernández M.C., Pelaez G., Pachkoria K., García-Ruiz E., et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005) 512-552
3. Andrade R.J., Robles M., Ortiz N., and Lucena M.I. Reexposure in hepatotoxicity: Concept testing or therapeutic accident?. Rev Esp Enferm Dig 100 (2008) 255-258
4. Andrade RJ, Lucena MI. Drug induced liver disease-mechanisms and diagnosis. En: McDonald JWD, Burroughs AK, Feagan BG (editores). Evidence-based gastroenterology and hepatology. 3 ed. London: Blackwell Ed; 2009.
5. Davern T.J. Hepatotoxicy of immunomodulating agents and the transplant situation. In: Kaplowitz N., and DeLeve L. (Eds). Drug-induced liver disease. 2 ed (2007), Informa Healthcare, Nueva York 662-681
6. Hinojosa J. Farmacología de la enfermedad inflamatoria intestinal. In: Gassull M.A., Gomollón F., Hinojosa J., and Obrador A. (Eds). Enfermedad inflamatoria intestinal. 3 ed (2007), Aran, Madrid 209-233
7. Hill R.B., Droke W.E., and Hays A.P. Hepatic lipid metabolism in the cortisone-treated rat. Exp Mol Pathol 4 (1965) 320-327
8. Jeanrenaud B. Effect of glucocorticoid hormones on fatty acid mobilization and reesterification in rat adipose and tissue. Biochem J 103 (1967) 627-633
9. Bhagwat A.G., and Deoghar S.D. Experimental hepatic injury produced in the rabbit by glucocorticoides. Arch Pathol 85 (1968) 346-356
10. Farrell G.C. Drugs and steatohepatitis. Semin Liver Dis 22 (2002) 185-194
11. Topal F., Ozaslan E., Akbulut S., Küçükazman M., Yüksel O., and Altiparmak E. Methylprednisolone-induced toxic hepatitis. Ann Pharmacother 40 (2006) 1868-1871
12. Rivero Fernández M., Riesco J.M., Moreira V.F., Moreno A., López San Román A., Arranz G., et al. Recurrent acute liver toxicity from intravenous methylprednisolone. Rev Esp Enferm Dig 100 (2008) 720-723
13. Gerber D., Bonham C., and Thompson A. Inmunosupresive agents: Recent developments in molecular action and clinical application. Transplant Proc 30 (1998) 1573-1579
14. Brynskov J. Cyclosporin for inflammatory bowel disease: Mechanisms and possible actions. Scand J Gastroenterol 28 (1993) 849-857
15. Haslam N., Hearing S.D., and Probert C.S. Audit of cyclosporin use in inflammatory bowel disease: Limited benefits, numerous side-effects. Eur J Gastroenterol Hepatol 12 (2000) 657-660
16. Cadranel J.F., Babany G., Oppolon P., and Erlinger S. Pharmacocinetique et effects hépatiques de la cyclosporine A. Gastroenterol Clin Biolog 16 (1992) 314-321
17. Wisecarver J.L., Earl R.A., Haven M.C., Timmins P.W., Shaw Jr. B.W., Stratta R.J., et al. Histologic changes in liver allograft biopsies associated with elevated whole blood and tissue cyclosporine concentrations. Mod Pathol 5 (1992) 611-616
18. Klintmalm G.B.G., Iwatsuki S., and Starzl T.E. Cyclosporin A hepatotoxicity in 66 renal allographt recipients. Transplantation 32 (1981) 488-489
19. Kassianides C., Nussenblatt R., Palestine A.G., Mellow S.D., and Hoofnagle J.H. Liver injury from cyclosporine A. Dig Dis Sci 35 (1990) 693-697
20. Actis G.C., Debernardi-Venon W., Lagget M., Marzano A., Ottobrelli A., Ponzetto A., et al. Hepatotoxicity of intravenous cyclosporin A in patients with acute ulcerative colitis on total parenteral nutrition. Liver 15 (1995) 320-323
21. Moore R.A., Greenberg E., and Tangen L. Cyclosporine-induced worsening of hepatic dysfunction in a patient with Crohn's disease and enterocutaneous fistula. South Med J 88 (1995) 843-844
22. Kowdley K.V., and Keeffe E.B. Hepatotoxicity of transplant immunosuppresive agents. Gastroenterol Clin North Am 24 (1995) 991-1001
23. Gulbis B., Adler M., Ooms H.A., Desmet J.M., Leclerc J.L., and Primo G. Liver-function studies in heart transplant recipients treated with cyclosporin A. Clin Chem 34 (1988) 1772-1774
24. Lewis J.H. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf 1 (2002) 159-172
25. Watkins P.B. The role of cytochromes P-450 in cyclosporine metabolism. J Am Acad Dermatol 23 (1990) 1301
26. Queneau P.E., Bertault-Peres P., Guitaoui M., Medsjian E., Durand A., and Montet J.C. Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat. Dig Dis Sci 39 (1994) 1581
27. Lorber M.I., Van Buren C.T., Flechner S.M., Williams C., and Kahan B.D. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation 43 (1987) 35-40
28. Alberu J., Gatica M., Cachafeiro-Vilar M., Robles-Díaz G., Bezaury P., Paz-Pinedo F., et al. Asymptomatic gallstones and duration of cyclosporine use in kidney transplant recipients. Rev Invest Clin 53 (2001) 396-400
29. Lowell J.A., Stratta R.J., Taylor R.J., Bynon J.S., Larsen J.L., and Nelson N.L. Cholelithiasis in pancreas and kidney transplant recipients with diabetes. Surgery 114 (1993) 863-864
30. Taniai N., Akimaru K., Ishikawa Y., Kanada T., Kakinuma D., Mizuguchi Y., et al. Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J Nippon Med Sch 75 (2008) 187-191
31. Niemczyk M., Wyzgal J., Perkowska A., Porowski D., and Leszek P. Sirolimus-associated hepatotoxicity in the kidney graft recipient. Transp Int 18 (2005) 1302-1303
32. Te H.S., Schiano T.D., Khuan S.F., Hanauer S.B., Conjeevaram H.S., and Baker A.L. Hepatic effects of long term methotrexate use in the tratment of inflamatory bowel disease. Am J Gastroenterol 95 (2000) 3150-3156
33. Chan E.S.L., and Cronstein B. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 4 (2002) 266-273
34. Cronstein B.N. Low-dose methotrexate: A main stay in the treatment of rheumatoid arthritis. Pharmacol Rev 57 (2005) 163-172
35. Mato J.M., and Lu S.C. Homocysteine, the bad thiol. Hepatology 41 (2005) 976-979
36. Ji C., and Kaplowitz N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 124 (2003) 1488-1499
37. Roenigk Jr. H.H., Maibach H.I., and Weinstein G.P. Methotrexate therapy for psoriasis: Guideline revisions. Arch Dermatol 108 (1973) 35
38. Dahl M.G.C., Gregory M.M., and Scheuer P.J. Liver damage due methotrexate in patients with psoriasis. Br Med J 1 (1971) 625-630
39. Boffa M.J., Chalmers R.J., Haboubi N.Y., Shomaf M., Mitchell D.M., et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: A reapprisal. Br J Dermatol 133 (1995) 774-778
40. Aberra F.N., and Lichtenstein G.R. Review article: Monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther 21 (2005) 307-319
41. Ashton R.E., Millward-Salder G.H., and White J.E. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 79 (1982) 229-232
42. Tang H., and Neuberger J. Review article: Methotrexate in gastroenterology. Dangerous villain or simply misunderstood?. Aliment Pharmacol Ther 10 (1996) 851-858
43. Kaplowitz N., and DeLeve L.D. Drug-induced liver disease (2003), Marcel Dekker, Inc., Nueva York
44. Rosenberg P., Urwitz H., Johannesson A., Ros A.-M., Lindholm J., Kinnman N., et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 46 (2007) 1111-1118
45. Oscan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse modle of type 2 diabetes. Science 313 (2006) 1137-1140
46. Ji C., and Kaplowitz N. ER stress: Can liver cope?. J Hepatol 45 (2006) 321-333
47. Aithal G. Dangerous liaisons: Drug, host and the environment. J Hepatol 46 (2007) 995-998
48. Aithal G.P., Haugk B., Das S., Card T., Burt A.D., and Record C.O. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: Are serial liver biopsies justified?. Aliment Pharmacol Ther 19 (2004) 391-399
49. Fraser A.G., Orchard T.R., and Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review. Gut 50 (2002) 485-489
50. Bastida G., Nos P., Aguas M., Beltrán B., Rubin A., Dasi F., et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflamatory bowel disease. Aliment Pharmacol Ther 22 (2005) 775-782
51. De Jong D.J., Derijks L.J., Naber A.H., Hooymans P.M., and Mulder C.J. Safety os thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol 239 (2003) 69-72
52. Vernier-Massouille G., Cosnes J., Lemann M., Marteau P., Reinisch W., and Laharie D. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 56 (2007) 1404-1409
53. Haboubi N.Y., Ali H.H., Whitwell H.L., and Ackrill P. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: Light microscopy and ultrastuctural observations. Am J Gastroenterol 83 (1988) 256-261
54. Tapner M.J., Jones B.E., Wu W.M., and Farrell G.C. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J Hepatol 40 (2004) 454-463
55. Gisbert J.P., González-Lama Y., and Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: A systematic review. Am J Gastroenterol 102 (2007) 1518-1527
56. Rulyak S.J., Saunders M.D., and Lee S.D. Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease. J Clin Gastroenterol 36 (2003) 234-237
57. Stork L.C., Broxson E.H., Sather H., Gaynon P., Matloub Y.H., Yanosfsky R., et al. Oral 6-thioguanine causes late onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukaemia. Gastroenterology 122 (2002) 833
58. Dubinsky M.C., Vasiliauskas E.A., Singh H., Abreu M.T., Papadakis K.A., Tran T., et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125 (2003) 298-303
59. Loiseau D., Degos F., Degott C., Carnot F., and Kreis H. Cholestasis after azathioprine administration in renal transplant recipients. Clin Transplant 1 (1987) 88-94
60. Hebert M.F., Taylor S.L., and Carithers R.L. Immunomodulating agents and the transplant situation. In: Kaplowitz N., DeLeve L.D., and Dekker M. (Eds). Drug induced liver disease (2003), Marcel Dekker, Nueva York 633-651
61. DeLeve L.D., Wang X., Kuhlenkamp J.F., and Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venooclusive disease. Hepatology 23 (1996) 589-599
62. Lee A.U., and Farrell G.C. Comparative toxicity of azathioprine to rat hepatocytes and sinusoidal endothelial cells in culture. In: Wisse E., Knook D.L., De Zanger R., and Fraser R. (Eds). Cells of the hepatic sinusoid vol 7 (1999), Kupffer Cell Foundation, Leiden 108-109
63. Lee A.U., and Farrell G.C. Mechanisms of azathioprine-induced injury to hepatocytes: Roles of glutathione depletion and mitochondrial injury. J Hepatol 35 (2001) 756-764
64. Romagnuolo J., Sadowski D.C., Lalor E., Jewell L., and Thomson A.B. Cholestatic hepatocellular injury with azathioprine: A case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 12 (1998) 479-483
65. Reuther L.O., Sonne J., Larsen N.E., Larsen B., Christensen S., Rasmussen S.N., et al. Pharmacological monitoring of azathioprine therapy. Scand J Gastroenterol 38 (2003) 972-977
66. Schwab M., Schaffeler E., Marx C., Fischer C., Lang T., Behrens C., et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: Impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12 (2002) 429-436
67. Raza M., Ahmad M., Gado A., and Al-Shabanah O.A. A comparasion of hepatoprotective activities of aminoguanidine and N-acetylcysteine in rat against the toxic damage induced by azathioprine. Comp Biochem Physiol C Toxicol Pharmacol 134 (2003) 451-456
68. Li E.K., Tam L.S., and Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 26 (2004) 447-459
69. Nash P., Thaci D., Behrens F., Falk F., and Kaltwasser J.P. Leflunomide improves psoriasis in patients with psoriatic arthritis: An in-depth analysis of data from the TOPAS study. Dermatology 212 (2006) 238-249
70. Cohen S., Cannon G.W., Schiff M., Weaver A., Fox R., Olsen N., et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 44 (2001) 1984-1992
71. EMEA pulic statement on leflunomide (Arava). Severe and serious hepatic reactions [citado 30 Abr 2009]. Disponible en: URL: www.emea.europa.eu/humandocs/PDFs/EPAR/Arava/561101en.pdf.
72. Antony T., Jose V.M., Paul B.J., and Thomas T. Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. Indian J Med Sci 60 (2006) 318-326
73. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg J, Kavanaugh A, et al. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2009;15. Epub ahead of print.
74. Sandborn W.J., and Targan S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology 122 (2002) 1592-1608
75. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., and Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168 (2002) 4620-4627
76. Antoni C.E., Kavanaugh A., Kirkham B., Tutuncu Z., Burmester G.R., and Schneider U. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 52 (2005) 1227
77. Becker M., Rose C.D., and McIlvain-Simpson G. Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis. J Rheumatol 31 (2004) 25-29
78. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare Harmful effects in randomized controlled trials. JAMA 295 (2006) 2275
79. Descalzo M.A. Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): informe de la situación, 26 de enero de 2006. Reumatol Clin 3 (2007) 4-20
80. Breedveld F.C. Therapeutic monoclonal antibodies. Lancet 355 (2000) 735-740
81. Papoutsaki M., Chimenti M.S., Costanzo A., Talamonti M., Zangrilli A., Giunta A., et al. Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with others biologic. J Am Acad Dermatol 57 (2007) 269-275
82. Cope A.P., Aderka D., Doherty M., Engelmann H., Gibbons D., Jones A.C., et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic disease. Arthitis Reum 35 (1992) 1160-1169
83. Mease P., Goffe B., Metz J., Vanderstoep A., Flinck B., and Burge D. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 356 (2000) 385-390
84. Thayu M., Markowitz J.E., Mamula P., Russo P.A., Muinos W.I., and Baldassano R.N. Hepatoesplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 40 (2005) 220-222
85. Larrey D. Hépatotoxicité des medicaments inmunosupresseurs. Conduite diagnostique. Gastroenterol Clin Biol 32 (2008) 194-204
86. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
87. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
88. FDA Briefing document. Arthritis Advisory Committee [15 Jun 2009]. Disponible en: URL:http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3930T1.htm
89. Ozorio G., McGarity B., Bak H., Jordan A.S., Lau H., and Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 187 (2007) 524-526
90. Castiella Eguzkiza A., Lucena M.I., Zapata-Morcillo E., Berenguer M., García- Bengoechea M., Martínez- Odriozola P., et al. Hepatitis autoinmune inducida por medicamentos. Rev Esp Enferm Dig 101 (2009) 73-74
91. Leak A.M., and Rincón-Aznar B. Hepatotoxicity associated with etanercept in psoriatic artritis. J Rheumatol 35 (2008) 2286-2288
92. Farah M., Al Rashidi A., Owen D.A., Yoshida E.M., and Reid G.D. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 35 (2008) 349-351
93. Davern TJ, Moawad D, Ferrell L. Liver injury from TNF antagonist-a class effect? AASLD Single Topic Conference on Drug Induced Liver Injury. Conferencia de la Asociación Americana para el estudio de la Enfermedad Hepática (AASLD); 2005
94. Massarotti M., and Marasini B. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol 22 (2009) 547-549
95. Swaminath A., Ullman T., Rosen M., Mayer L., Lichtiger S., and Abreu T. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther 29 (2009) 273-278
96. García-Aparicio A.M., Rey-Rey J., Hernández-Sanz A., and Sampedro J. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 26 (2007) 811-813
97. Thiefin G., Morelet A., Heurgue A., Diebold M.D., and Eschard J.P. Infliximab-induced hepatitis: Absence of cross-toxicity with etanercept. Joint Bone Espine 75 (2008) 737-739
98. Larrey D. Liver toxicity of TNF-α antagonists. Joint Bone Spine 75 (2008) 636-638
99. Brimhall A.K., King L.N., Licciardone J.C., Jacobe H., and Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials. Br J Dermatol 159 (2008) 274-285
100. Kallinowski B., Haseroth K., Marinos G., Hanck C., Stremmel W., Theilmann L., et al. Induction of tumor necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 111 (1998) 269-277
101. Monsalve-DeCastillo F., Romero T.A., Estevez J., Costa L.L., Atencio R., Porto L., et al. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clin Diagn Lab Immunol 9 (2002) 1372-1375
102. Zylberberg H., Rimaniol A.C., Pol S., Masson A., D Groote D., Berthelot P., et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: A correlation with histological fibrosis and activity. J Hepatol 30 (1999) 185-191
103. Calabrese L.H., Zein N., and Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: Hepatitis C, hepatitis B and HIV infection. Ann Rheum Dis 63 (2004) 18-24
104. Carroll M.B., and Bond M.I. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38 (2008) 208-217
105. Li S., Kaur P.P., Chan V., and Berney S. Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: A retrospective record review of 11 patients. Clin Rheumatol 28 (2009) 787-791
106. Michel M., Duvoux C., Hezode C., and Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 30 (2003) 1624-1625
107. Millonig G., Kern M., Ludwiczek O., Nachbaur K., and Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: Need for HBV-screening?. World J Gastroenterol 12 (2006) 974-976
108. Carroll M.B., and Bond M.I. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38 (2008) 208-217
109. Scott D.L., and Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355 (2006) 704-712